January 23, 2025
2 min read
Save
ACC announces lineup of 2025 Scientific Session late-breakers
Key takeaways:
- The American College of Cardiology released the late-breaking clinical trials to be presented at its 2025 Scientific Session.
- The meeting will feature six late-breaking science sessions across the 3-day meeting.
The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 29-31 in Chicago and online.
The lineup is as follows:
Late-Breaking Clinical Trials I: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials
- primary and secondary outcomes of the women’s ischemia trial to reduce events in nonobstructive CAD;
- primary results from the phase 3b, randomized, placebo-controlled, double-blind STRIDE trial of once-weekly semaglutide (Ozempic, Novo Nordisk) on functional capacity in people with diabetes and peripheral artery disease; and
- API-CAT study of extended anticoagulation with reduced- vs. full-dose apixaban (Eliquis, Bristol Myers Squibb/Pfizer) in patients with cancer-associated venous thromboembolism.
Late-Breaking Clinical Trials II: Joint ACC/JAMA Late-Breaking Clinical Trials
- primary results of the SOUL trial of oral semaglutide (Rybelsus, Novo Nordisk) to reduce CV events in people with diabetes with atherosclerotic CVD and/or chronic kidney disease;
- trial to evaluate the efficacy of lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor, for uncontrolled hypertension in patients already on a standardized antihypertensive regimen;
- development and external validation of a deep learning ECG model for risk stratification for coronary revascularization need in the ED; and
- dapagliflozin (Farxiga, AstraZeneca) for patients undergoing transcatheter aortic valve replacement.
Late-Breaking Clinical Trials III
- RIVAWAR trial of rivaroxaban (Xarelto, Janssen/Bayer) compared with warfarin for patients with acute left ventricular thrombus after MI;
- phase 3, randomized, active-control superiority study of four-factor prothrombin complex concentrate compared with frozen plasma in bleeding adult cardiac surgery patients with coagulopathy;
- results of the phase 3 REVERSE-IT trial; and
- study comparing dual antiplatelet therapy duration after coronary stenting in either high or low bleeding risk populations.
Late-Breaking Clinical Trials IV
- results of the MIGHTy-Heart trial comparing effectiveness of mobile integrated health with transitions of care coordinator in patients with HF;
- trial of liberal fluid intake compared with fluid restriction in chronic HF;
- EquiOx study evaluating pulse oximeter bias across a range of skin pigment in critically ill adults; and
- FAIR-HF2 trial of ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic HF.
Late-Breaking Clinical Trials V: Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials
- PROTECT-TAVI trial of routine cerebral embolic protection during TAVR;
- ALIGN-AR trial evaluating outcomes among the first 500 patients treated with a dedicated transcatheter aortic valve for pure aortic regurgitation;
- 5-year outcomes after TAVR compared with surgical AVR in low-risk patients with aortic stenosis; and
- FLAVOUR II trial comparing angiography-derived fractional flow reserve-guided with IVUS-guided PCI strategies.
Late-Breaking Clinical Trials VI
- 2-year outcomes from the TRILUMINATE Pivotal trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation;
- FFR-guided PCI compared with CABG: the 5-year results of the FAME 3 trial;
- clopidogrel compared with aspirin for long-term maintenance monotherapy in patients with high ischemic risk after PCI; and
- alliance for secondary prevention after ACS.
In addition to the six late-breaking science sessions, the meeting will feature two “deep-dive” sessions to provide additional insight on key trials; five featured clinical research sessions; and two clinical and investigative horizons sessions.
Healio will be on-site in Chicago to report the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and more. Follow our breaking updates here and via @CardiologyToday on X (formerly Twitter).
Published by: